Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The copper-bound peptide, Glycyl-L-Histidyl-L-Lysine-Copper(II) (GHK-Cu), is a naturally occurring complex ubiquitous in human biological fluids such as plasma, saliva, and urine
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
YFP/CFP) in Gipr -labelled cells in the AP, reflecting an increase in cAMP levels (Fig
Copper tripeptide-3 stimulates the elongation of human hair follicles and proliferation of dermal papilla cells
The two peptides therefore engage non-overlapping cellular and signalling pathways that both converge on tissue repair and remodeling outcomes
Chemokine and Chemokine Receptor Expression in Paired Peripheral Blood Mononuclear Cells and Synovial Tissue of Patients With Rheumatoid Arthritis, Osteoarthritis, and Reactive Arthritis
US$ 20.70
US$ 22.95
US$ 28.31
US$ 27.58
US$ 24.51
US$ 28.76
